Navigation Links
Cell-death receptor links cancer susceptibility and inflammation
Date:12/27/2007

mice without the TRAIL receptor that were irradiated developed chronic pneumonia, an inflammatory response, as well tumors, evidence pointing to the connection between cancer and inflammation via TRAIL. One benefit of this work is that it provides a new and unanticipated model implicating a TRAIL pathway deficiency in the chronic toxicity of radiation therapy, he notes. Inflammation is a common late and serious side-effect of radiation treatment in people.

El-Deiry and his team are now looking within tumor tissue for inflammatory molecules as clues to how cancer and inflammation are coupled. Our work with TRAIL and its receptor in mouse models represents a new way to look at cancer susceptibility and its potential therapy in humans as well as new ways to decrease debilitating radiation side-effects experienced by cancer patients, says El-Deiry.

Co-authors in addition to El-Deiry are Niklas Finnberg from Penn and Andres J.P. Klein-Szanto from Fox Chase Cancer Center, Philadelphia. This research was funded in part by the National Cancer Institute.

This release can be found at www.pennhealth.com/news.


'/>"/>
Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
2. Low level of neuronal receptor linked to mild cognitive impairment and Alzheimers disease
3. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
4. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
5. Food restriction increases dopamine receptor levels in obese rats
6. Quest Diagnostics Licenses Technology Underlying SensiTrop(TM) HIV Co-Receptor Tropism Test from Pathway Diagnostics
7. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
8. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
9. Receptor protein appears to be key in breakdown of kidney filtration
10. Pathway links inflammation, angiogenesis and breast cancer
11. Research Links TV/Video Game Playing With Child Obesity; Health Experts Back a New Approach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... Javon Bea Mercy Health System CEO ... capable by the State of Illinois, enabling potential stroke ... Hospital. , The hospital was required to submit data ... stroke according to national standards of care for stroke ... bypass hospitals not designated as an Emergent Stroke Ready ...
(Date:2/28/2015)... 28, 2015 Memphis, TN: MedixSafe has ... for a new security reader named Guardian 2. ... is a new biometric scanner that significantly increases ... features, the new biometric scanner provides fast and ... , MedixSafe narcotics lockers with Vanguard ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 1Heart ... and showcased emerging brand at Houston Texas Franchise ... Las Vegas sending its executive delegates headed by ... Business Development and Training Randolph Clarito. , Franchise ... was held last February 4-7 and featured Franchise ...
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 ... Devices (IPD), has introduced miniature, wire bondable, silicon ESD ... Power LED markets. The ESD88NP and ... currents away from sensitive LED and IC products. ... Multilayer Varistors (MLV). All devices meet the requirements ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 ... “cutters”, are often misunderstood, misdiagnosed and therefore ... to healthy lives. Jacksonville-based addiction treatment ... of its highly acclaimed Lakeview Professional Lecture ... interested in understanding this complicated condition. ...
Breaking Medicine News(10 mins):Health News:Mercy Harvard Hospital Recognized as Leader in Stroke Care - Javon Bea 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 3Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3Health News:Lakeview Health to Host Important Workshop Tackling the Rising Issue of ‘Cutters’ on March 27 2
... Association for Cancer Research and the International Association for the ... M.D., for his leadership in lung cancer research at the ... conference, held from Jan. 11-14, 2010, drew more than 300 ... and the James Dudley chair in cancer research at the ...
... control in patients with type 2 diabetes, according to ... Chicago. The study "demonstrates for the first time ... OSA severity and glucose control in patients with type ... instructor of medicine at the University of Chicago. ...
... Serious complication called empyema has doubled in young children, ... Since the PCV7 early childhood vaccine for bacterial pneumonia ... number of children hospitalized for pneumonia because of pneumococcus ... decreased overall, new research shows. , But the scientists ...
... ... source of information for dental professionals on the latest trends in restorative materials, ... ... the leading provider of online daily news and information for the dental community, ...
... ... expatriates are calling MEDEX Global Group for assistance in trying to leave the country, ASI ... members of the press into the Haitian capital, Port-au-Prince. , ... ,Baltimore, MD (Vocus) January 14, 2010 -- In the ...
... PARK, Ill., Jan. 14 A new diagnostic tool, ... a pelvic mass is benign or malignant, is now available in ... in the assessment of epithelial ovarian cancer, the most lethal form ... ARCHITECT systems, is the first automated HE4 test available ...
Cached Medicine News:Health News:Lung cancer conference leaders honor Paul A. Bunn Jr., M.D. 2Health News:Obstructive sleep apnea may worsen diabetes 2Health News:Lung Infection Up in Wake of Kids' Pneumonia Vaccine 2Health News:DrBicuspid.com Announces 3M ESPE Exclusive Sponsorship of its Restoratives Community 2Health News:DrBicuspid.com Announces 3M ESPE Exclusive Sponsorship of its Restoratives Community 3Health News:An Earthquake Emergency: MEDEX and ASI Group Quickly Respond to the Situation in Haiti 2Health News:An Earthquake Emergency: MEDEX and ASI Group Quickly Respond to the Situation in Haiti 3Health News:Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test 2
(Date:2/27/2015)... , Feb. 27, 2015  Following a bipartisan ... that moved H.R. 284, the Medicare DMEPOS Competitive ... Association for Homecare (AAHomecare) released a statement praising ... to pass the legislation. "Today,s mark-up ... House Ways and Means Committee is a critical ...
(Date:2/27/2015)... HOUSTON, TX , Feb. 27, 2015 ... EPI) and Bloom Burton & Co. Ltd. ("Bloom Burton") ... lock-up (the "Lock-Up") 2,353,130 common shares of the Company ... subject to the Lock-Up. Of the Common Shares released ... immediately upon release from the Lock-Up while the remainder ...
(Date:2/27/2015)...   Synageva BioPharma Corp. (Synageva) (NASDAQ: ... therapeutic products for rare diseases, joins the National ... for Rare Diseases™ (EURORDIS™), The Global Genes Project™, ... Disease Day. On the last day ... other participants conduct special events to raise awareness ...
Breaking Medicine Technology:Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... with investigators worldwide to develop new treatments for ... diverse forms of cancer - Plenary ... of patients with early-stage breast cancer, - Four oral sessions to feature ... study in renal cell ...
... Hispanics/Latinos, People ... with Diabetes and Obese Individuals, PARSIPPANY, N.J., ... presented at the American Society of,Hypertension,s Twenty- Third Annual ... powerful combination drug AZOR(TM),(amlodipine and olmesartan medoxomil) safely and ...
Cached Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7
Inquiry 4Fr, 5Fr and 6Fr diagnostic electrophysiology catheters offer simple, precise distal control with it's patented Easy-Hand steering mechanism....
... offers patient monitoring products for hospital ... medium acuity monitoring. The Envoy patient ... The Enmove monitor offers a ... complement the Envoy. The Ensemble ...
... The Mayfield Triad Skull Clamp, compatible with ... visual indication of clamping force on all ... user with the possibility of adjusting the ... can easily be increased or decreased by ...
Protein-to-creatinine ratio is key to earlier detection of Kidney Disease...
Medicine Products: